Stryker Co. (NYSE:SYK) Stock Position Increased by Mutual Advisors LLC

Mutual Advisors LLC boosted its position in shares of Stryker Co. (NYSE:SYK) by 13.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,331 shares of the medical technology company’s stock after buying an additional 769 shares during the quarter. Mutual Advisors LLC’s holdings in Stryker were worth $2,417,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Public Sector Pension Investment Board lifted its stake in Stryker by 79.0% during the second quarter. Public Sector Pension Investment Board now owns 12,579 shares of the medical technology company’s stock valued at $4,280,000 after purchasing an additional 5,553 shares during the last quarter. Insigneo Advisory Services LLC lifted its position in shares of Stryker by 31.9% during the 2nd quarter. Insigneo Advisory Services LLC now owns 2,150 shares of the medical technology company’s stock valued at $679,000 after acquiring an additional 520 shares during the last quarter. AXA S.A. boosted its stake in shares of Stryker by 11.0% during the 2nd quarter. AXA S.A. now owns 91,054 shares of the medical technology company’s stock worth $30,981,000 after acquiring an additional 9,052 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Stryker by 9.7% in the 2nd quarter. AQR Capital Management LLC now owns 125,333 shares of the medical technology company’s stock worth $42,485,000 after acquiring an additional 11,075 shares during the last quarter. Finally, APG Asset Management N.V. raised its position in shares of Stryker by 2.2% during the second quarter. APG Asset Management N.V. now owns 223,007 shares of the medical technology company’s stock worth $70,798,000 after purchasing an additional 4,902 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.90% of the company’s stock.

Stryker Price Performance

Shares of SYK opened at $393.79 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm has a market cap of $150.12 billion, a PE ratio of 42.21, a PEG ratio of 2.68 and a beta of 0.95. Stryker Co. has a twelve month low of $307.23 and a twelve month high of $398.20. The firm’s 50 day moving average price is $375.82 and its 200 day moving average price is $360.16.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. Stryker’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.46 earnings per share. As a group, research analysts expect that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.85%. This is an increase from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend is Tuesday, December 31st. Stryker’s dividend payout ratio (DPR) is presently 36.01%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SYK. Evercore ISI increased their price target on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 target price on shares of Stryker in a report on Tuesday, January 7th. Canaccord Genuity Group boosted their price target on shares of Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. BTIG Research lifted their price objective on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, Truist Financial boosted their target price on shares of Stryker from $380.00 to $409.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $405.80.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.